26.52
+0.3(+1.14%)
Currency In USD
| Previous Close | 26.22 |
| Open | 26.18 |
| Day High | 26.92 |
| Day Low | 25.85 |
| 52-Week High | 28.49 |
| 52-Week Low | 9.03 |
| Volume | 593,347 |
| Average Volume | 1.13M |
| Market Cap | 1.99B |
| PE | -31.2 |
| EPS | -0.85 |
| Moving Average 50 Days | 19.58 |
| Moving Average 200 Days | 14.61 |
| Change | 0.3 |
If you invested $1000 in Zymeworks Inc. (ZYME) since IPO date, it would be worth $2,040 as of December 04, 2025 at a share price of $26.52. Whereas If you bought $1000 worth of Zymeworks Inc. (ZYME) shares 5 years ago, it would be worth $482.27 as of December 04, 2025 at a share price of $26.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zymeworks Announces Participation in Upcoming Conferences
GlobeNewswire Inc.
Dec 02, 2025 9:05 PM GMT
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting ant
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
GlobeNewswire Inc.
Nov 18, 2025 6:01 AM GMT
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
GlobeNewswire Inc.
Nov 18, 2025 6:00 AM GMT
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatama